Shamburg News · 8-K filed Nov 5, 2026, 6:32 AM EST
Evommune to Host Webcast on EVO570 and Expanding Immunology Portfolio
EVMN · Evommune, Inc.
- Other event
- Material agreement
- Reg FD disclosure
- Materiality: low
Evommune, Inc. announced on November 5, 2026 that a pre-recorded webcast on EVO570, an oral VAV1-directed molecular glue degrader, will be available at 8:30 a.m. ET that day. Management is to discuss the previously announced exclusive license agreement with Hinova Pharmaceuticals for worldwide rights outside Greater China. The filing furnishes the press release under Item 7.01 and states the webcast will not include a live question-and-answer session.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-448443.
Written from the filing by Shamburg Markets. Figures are as reported by the company.